Yarrow Bioscience Reports Q3 2026 Net Loss of $9.72 Million

PUBT · 2d ago
Yarrow Bioscience Reports Q3 2026 Net Loss of $9.72 Million
  • Yarrow Bioscience reported a third-quarter 2026 net loss of $9.72 million.
  • Cash and cash equivalents more than doubled from December 31, 2025, to $268.86 million at September 30, 2026.
  • The cash balance is expected to fund operations into 2030, including completion of the DIRECTION-GD trial.
  • Enrollment continues in DIRECTION-GD’s Phase 2a portion, with topline results expected in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yarrow Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112712357) on November 12, 2026, and is solely responsible for the information contained therein.